TY - JOUR
T1 - Ten-year outcome of tardive dyskinesia
AU - Gardos, George
AU - Casey, Daniel E.
AU - Cole, Jonathan O.
AU - Perenyi, Andras
AU - Kocsis, Edit
AU - Arato, Mihaly
AU - Samson, Jacqueline A.
AU - Conley, Caitlyn
PY - 1994/6
Y1 - 1994/6
N2 - Objective: The purpose of this study was to assess the long-term outcome of patients with tardive dyskinesia. Method: A group of 122 neuroleptic-treated Hungarian outpatients were assessed for tardive dyskinesia on the Abnormal Involuntary Movement Scale and the Tardive Dyskinesia Rating Scale by the same rater over a 10-year period. Results: Sixty-three of the patients received both 5- and 10-year follow-up assessments and are the subjects of this report. The overall prevalence of tardive dyskinesia in this group changed little over time; it was 30.2% at baseline, 36.5% at 5 years, and 31.7% at 10 years. However, there were changes in the tardive dyskinesia status of individual patients; 11 patients had remissions, and 12 who did not have tardive dyskinesia at the baseline assessment had developed it by the 10-year assessment. These two subgroups did not differ significantly on demographic and drug history variables. Outcome of tardive dyskinesia was not significantly related to neuroleptic treatment or to age. Conclusions: The data of this 10-year follow-up study provide evidence for the long-term stability of tardive dyskinesia and for the feasibility of maintenance neuroleptic therapy for chronic psychotic patients who have tardive dyskinesia.
AB - Objective: The purpose of this study was to assess the long-term outcome of patients with tardive dyskinesia. Method: A group of 122 neuroleptic-treated Hungarian outpatients were assessed for tardive dyskinesia on the Abnormal Involuntary Movement Scale and the Tardive Dyskinesia Rating Scale by the same rater over a 10-year period. Results: Sixty-three of the patients received both 5- and 10-year follow-up assessments and are the subjects of this report. The overall prevalence of tardive dyskinesia in this group changed little over time; it was 30.2% at baseline, 36.5% at 5 years, and 31.7% at 10 years. However, there were changes in the tardive dyskinesia status of individual patients; 11 patients had remissions, and 12 who did not have tardive dyskinesia at the baseline assessment had developed it by the 10-year assessment. These two subgroups did not differ significantly on demographic and drug history variables. Outcome of tardive dyskinesia was not significantly related to neuroleptic treatment or to age. Conclusions: The data of this 10-year follow-up study provide evidence for the long-term stability of tardive dyskinesia and for the feasibility of maintenance neuroleptic therapy for chronic psychotic patients who have tardive dyskinesia.
UR - http://www.scopus.com/inward/record.url?scp=0028308428&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028308428&partnerID=8YFLogxK
U2 - 10.1176/ajp.151.6.836
DO - 10.1176/ajp.151.6.836
M3 - Article
C2 - 7910437
AN - SCOPUS:0028308428
SN - 0002-953X
VL - 151
SP - 836
EP - 841
JO - American Journal of Psychiatry
JF - American Journal of Psychiatry
IS - 6
ER -